Search
Results: 28740
Which Neuropsychological Tests? Predicting Cognitive Decline and Dementia in Parkinson's Disease in the ICICLE-PD Cohort.
Rachael A Lawson, Caroline H Williams-Gray, Marta Camacho, Gordon W Duncan, Tien K Khoo, David P Breen, Roger A Barker, Lynn Rochester, David J Burn, Alison J Yarnall, ICICLE-PD study group
May 28, 2021
BACKGROUND: Cognitive impairment is common in Parkinson's disease (PD), with 80% cumulatively developing dementia (PDD). OBJECTIVE: We sought to identify tests that are sensitive to change over time above normal ageing so as to...
Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease
Cristina Nombela, James B Rowe, Sophie E Winder-Rhodes, Adam Hampshire, Adrian M Owen, David P Breen, Gordon W Duncan, Tien K Khoo, Alison J Yarnall, Michael J Firbank, Patrick F Chinnery, Trevor W Robbins, John T O'Brien, David J Brooks, David J Burn, ICICLE-PD study group, Roger A Barker
Feb 02, 2016
Parkinson’s disease Cognition Functional MRI Genetics Aged Apolipoproteins E Brain Catechol O-Methyltransferase Cognition Cognition Disorders Cohort Studies Female Humans Image Processing Computer-Assisted Imagination Longitudinal Studies Magnetic Resonance Imaging Male Memory Middle Aged Mitogen-Activated Protein Kinases Neuroimaging Neuropsychological Tests Parkinson Disease Psychomotor Performance Rotation Space Perception tau Proteins
Cognitive impairment in Parkinson's disease
RA Lawson, AJ Yarnall, F Johnston, GW Duncan, TK Khoo, D Collerton, JP Taylor, DJ Burn, ICICLE-PD study group
Apr 12, 2018
BACKGROUND: The quality of life (QoL) of informal caregivers of people with Parkinson's disease (PD) (PwP) can be affected by the caring role. Because of cognitive symptoms and diminished activities of daily living, in addition...
Cognitive decline and quality of life in incident Parkinson's disease
Rachael A Lawson, Alison J Yarnall, Gordon W Duncan, David P Breen, Tien K Khoo, Caroline H Williams-Gray, Roger A Barker, Daniel Collerton, John-Paul Taylor, David J Burn, ICICLE-PD study group
Apr 12, 2018
INTRODUCTION: Parkinson's disease dementia (PDD) is associated with poorer quality of life (QoL). Prior to the onset of PDD, many patients experience progressive cognitive impairment. There is a paucity of longitudinal studies...
Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.
Rachael A Lawson, Alison J Yarnall, Gordon W Duncan, David P Breen, Tien K Khoo, Caroline H Williams-Gray, Roger A Barker, David J Burn, ICICLE-PD study group
Aug 16, 2017
BACKGROUND: Mild cognitive impairment (MCI) is common in early Parkinson's disease (PD). We evaluated the stability of PD-MCI over time to determine its clinical utility as a marker of disease. METHODS: 212 newly diagnosed...
Anxiety is associated with cognitive impairment in newly-diagnosed Parkinson's disease.
Nadeeka NW Dissanayaka, Rachael A Lawson, Alison J Yarnall, Gordon W Duncan, David P Breen, Tien K Khoo, Roger A Barker, David J Burn, ICICLE-PD study group
Aug 17, 2017
INTRODUCTION: Anxiety and mild cognitive impairment (MCI) are prevalent non-motor manifestations of Parkinson's disease (PD). While few studies have demonstrated a possible link between cognitive dysfunction and anxiety in PD...
Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.
Lourdes Ortiz-Fernández, Francisco David Carmona, Raquel López-Mejías, Maria Francisca González-Escribano, Paul A Lyons, Ann W Morgan, Amr H Sawalha, Peter A Merkel, Kenneth GC Smith, Miguel A González-Gay, Javier Martín, UK GCA Consortium, Turkish Takayasu Study Group, Vasculitis Clinical Research Consortium, IgAV Study Group, AAV Study group Spanish GCA Study Group
Apr 18, 2018
OBJETIVE: Systemic vasculitides represent a heterogeneous group of rare complex diseases of the blood vessels with a poorly understood aetiology. To investigate the shared genetic component underlying their predisposition, we...
Autoantibodies outcomes research systemic sclerosis Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Case-Control Studies Epigenesis Genetic Female Genetic Loci Genetic Predisposition to Disease Giant Cell Arteritis HLA-DQ Antigens HLA-DQ beta-Chains Humans Jumonji Domain-Containing Histone Demethylases Linkage Disequilibrium Male Phenotype Polymorphism Single Nucleotide Protein Array Analysis Systemic Vasculitis Takayasu arteritis
Investigation and Management of Apparently Sporadic Central Nervous System Haemangioblastoma for Evidence of Von Hippel–Lindau Disease
Hugh Furness, Louay Salfity, Johanna Devereux, Dorothy Halliday, Helen Hanson, Deborah M. Ruddy, UK VHL Study Group UK VHL Study Group, Neha Shah, George Sultana, Emma R. Woodward, Richard N. Sandford, Katie M. Snape, Eamonn R. Maher
Sep 17, 2021
Haemangioblastomas are rare, highly vascularised tumours that typically occur in the cerebellum, brain stem and spinal cord. Up to a third of individuals with a haemangioblastoma will have von Hippel–Lindau (VHL) disease....
Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson’s Disease Cohort (ICICLE-PD)
J. K. Dlay, G. W. Duncan, T. K. Khoo, C. H. Williams-Gray, D. P. Breen, R. A. Barker, D. J. Burn, R. A. Lawson, A. J. Yarnall
Feb 03, 2020
Background: Cross-sectional studies have identified that the prevalence of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) ranges from 70−89%. However, there are few longitudinal studies determining the impact of NPS...
Progression of Neuropsychiatric Symptoms over Time in an Incident Parkinson's Disease Cohort (ICICLE-PD).
JK Dlay, GW Duncan, TK Khoo, CH Williams-Gray, DP Breen, RA Barker, DJ Burn, RA Lawson, AJ Yarnall
Feb 28, 2020
BACKGROUND: Cross-sectional studies have identified that the prevalence of neuropsychiatric symptoms (NPS) in Parkinson's disease (PD) ranges from 70-89%. However, there are few longitudinal studies determining the impact of NPS...
A Modified Progressive Supranuclear Palsy Rating Scale.
Marie-Therese Grötsch, Gesine Respondek, Carlo Colosimo, Yaroslau Compta, Jean Christophe Corvol, Joaquim Ferreira, Meret Koroni Huber, Martin Klietz, Lea FM Krey, Johannes Levin, Milica Jecmenica-Lukic, Daniel Macías-García, Wassilios G Meissner, Pablo Mir, Huw Morris, Christer Nilsson, James B Rowe, Klaus Seppi, Maria Stamelou, John C van Swieten, Gregor Wenning, Teodoro del Ser, Lawrence I Golbe, Günter U Höglinger, the ProPSP Study Group, and the Movement Disorder Society-Endorsed PSP Study Group Describe PSP Study Group
Jan 26, 2021
BACKGROUND: The Progressive Supranuclear Palsy Rating Scale is a prospectively validated physician-rated measure of disease severity for progressive supranuclear palsy. We hypothesized that, according to experts' opinion...
Embracing Monogenic Parkinson's Disease
Eva-Juliane Vollstedt, Susen Schaake, Katja Lohmann, Shalini Padmanabhan, Alexis Brice, Suzanne Lesage, Christelle Tesson, Marie Vidailhet, Isabel Wurster, Faycel Hentati, Anat Mirelman, Nir Giladi, Karen Marder, Cheryl Waters, Stanley Fahn, Meike Kasten, Norbert Brüggemann, Max Borsche, Tatiana Foroud, Eduardo Tolosa, Alicia Garrido, Grazia Annesi, Monica Gagliardi, Maria Bozi, Leonidas Stefanis, Joaquim J Ferreira, Leonor Correia Guedes, Micol Avenali, Simona Petrucci, Lorraine Clark, Ekaterina Y Fedotova, Natalya Y Abramycheva, Victoria Alvarez, Manuel Menéndez-González, Silvia Jesús Maestre, Pilar Gómez-Garre, Pablo Mir, Andrea Carmine Belin, Caroline Ran, Chin-Hsien Lin, Ming-Che Kuo, David Crosiers, Zbigniew K Wszolek, Owen A Ross, Joseph Jankovic, Kenya Nishioka, Manabu Funayama, Jordi Clarimon, Caroline H Williams-Gray, Marta Camacho, Mario Cornejo-Olivas, Luis Torres-Ramirez, Yih-Ru Wu, Guey-Jen Lee-Chen, Ana Morgadinho, Teeratorn Pulkes, Pichet Termsarasab, Daniela Berg, Gregor Kuhlenbäumer, Andrea A Kühn, Friederike Borngräber, Giuseppe de Michele, Anna De Rosa, Alexander Zimprich, Andreas Puschmann, George D Mellick, Jolanta Dorszewska, Jonathan Carr, Rosangela Ferese, Stefano Gambardella, Bruce Chase, Katerina Markopoulou, Wataru Satake, Tatsushi Toda, Malco Rossi, Marcelo Merello, Timothy Lynch, Diana A Olszewska, Shen-Yang Lim, Azlina Ahmad-Annuar, Ai Huey Tan, Bashayer Al-Mubarak, Hasmet Hanagasi, Dariusz Koziorowski, Sibel Ertan, Gençer Genç, Patricia de Carvalho Aguiar, Melinda Barkhuizen, Marcia MG Pimentel, Rachel Saunders-Pullman, Bart van de Warrenburg, Susan Bressman, Mathias Toft, Silke Appel-Cresswell, Anthony E Lang, Matej Skorvanek, Agnita JW Boon, Rejko Krüger, Esther M Sammler, Vitor Tumas, Bao-Rong Zhang, Gaetan Garraux, Sun Ju Chung, Yun Joong Kim, Juliane Winkelmann, Carolyn M Sue, Eng-King Tan, Joana Damásio, Péter Klivényi, Vladimir S Kostic, David Arkadir, Mika Martikainen, Vanderci Borges, Jens Michael Hertz, Laura Brighina, Mariana Spitz, Oksana Suchowersky, Olaf Riess, Parimal Das, Brit Mollenhauer, Emilia M Gatto, Maria Skaalum Petersen, Nobutaka Hattori, Ruey-Meei Wu, Sergey N Illarioshkin, Enza Maria Valente, Jan O Aasly, Anna Aasly, Roy N Alcalay, Avner Thaler, Matthew J Farrer, Kathrin Brockmann, Jean-Christophe Corvol, Christine Klein, MJFF Global Genetic Parkinson's Disease Study Group
Jan 24, 2023
BACKGROUND: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the...
Longitudinal diffusion tensor imaging changes in early Parkinson's disease
Thais Minett, Li Su, Elijah Mak, Guy Williams, Michael Firbank, Rachael A Lawson, Alison J Yarnall, Gordon W Duncan, Adrian M Owen, Tien K Khoo, David J Brooks, James B Rowe, Roger A Barker, David Burn, John T O'Brien
Jul 30, 2018
Assessment of cognitive disorders DTI longitudinal study mild cognitive impairment Parkinson’s disease Aged Analysis of Variance Cognition Disorders Cohort Studies Diffusion tensor imaging Female Humans Image Processing Computer-Assisted Linear Models Male Mental Status and Dementia Tests Middle Aged Neuropsychological Tests Parkinson Disease
A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease
CM Sackley, C Rick, P Au, MC Brady, G Beaton, C Burton, M Caulfield, S Dickson, F Dowling, M Hughes, N Ives, S Jowett, P Masterson-Algar, A Nicoll, S Patel, CH Smith, R Woolley, CE Clarke, PD COMM Collaborative Group
May 27, 2021
BACKGROUND: Parkinson's disease (PD) affects approximately 145,519 people in the UK. Speech impairments are common with a reported prevalence of 68%, which increase physical and mental demands during conversation, reliance on...
dysarthria Idiopathic Parkinson’s disease Lee Silverman voice treatment randomised controlled trial speech and language therapy Clinical Trials Phase III as Topic Cost-Benefit Analysis Humans Language Therapy Multicenter Studies as Topic Parkinson Disease Quality of life Randomized Controlled Trials as Topic speech therapy Surveys and Questionnaires United Kingdom Voice Voice Disorders
Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease
Carmen Martin-Ruiz, Caroline H Williams-Gray, Alison J Yarnall, John J Boucher, Rachael A Lawson, Ruwani S Wijeyekoon, Roger A Barker, Claire Kolenda, Craig Parker, David J Burn, Thomas von Zglinicki, Gabriele Saretzki
Oct 18, 2019
Parkinson’s disease biomarker COGNITIVE IMPAIRMENT Dementia Inflammation p16 p21 Senescence telomere Length Aged Aged 80 and over aging Biomarkers Cognitive Dysfunction Cyclin-Dependent Kinase Inhibitor p16 Cyclin-Dependent Kinase Inhibitor p21 Dementia Disease Progression Female Health Surveys Humans Inflammation Longitudinal Studies Male Middle Aged Parkinson Disease Prognosis Telomere Shortening
Cerebral glucose metabolism and cognition in newly diagnosed Parkinson’s disease
MJ Firbank, AJ Yarnall, RA Lawson, GW Duncan, TK Khoo, GS Petrides, JT O’Brien, Roger Alistair Barker, RJ Maxwell, DJ Brooks, DJ Burn
Aug 16, 2017
This is the final version of the article. It first appeared from BioMed Central via http://dx.doi.org/10.1136/jnnp-2016-313918
Published by: Journal of Neurology, Neurosurgery and Psychiatry
Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease
On the appearance of nitrite anion in [PdX(OAc)L<sub>2</sub>] and [Pd(X)(C∧N)L] syntheses (X = OAc or NO<sub>2</sub>)
S E Bajwa, T E Storr, Lauren E Hatcher, T J Williams, C G Baumann, A C Whitwood, D R Allan, S J Teat, Paul R Raithby, I J S Fairlamb
May 01, 2012
Pd 3(OAc) 5NO 2, an impurity in "Pd(OAc) 2" {formally Pd 3(OAc) 6}, emerges as a serious issue in the synthesis of pure Pd II complexes derived from Pd(OAc) 2, for example in our C-H activation precatalyst, Pd(OAc) 2(pip) 2 (pip...
Emergency surgery for splenic flexure cancer
Nicola de'Angelis, Eloy Espin, Frederic Ris, Filippo Landi, Bertrand Le Roy, Federico Coccolini, Valerio Celentano, Angela Gurrado, Denis Pezet, Giorgio Bianchi, Riccardo Memeo, Giulio C Vitali, Alejandro Solis, Christine Denet, Salomone Di Saverio, Gian Luigi de'Angelis, Miquel Kraft, Paula Gonzálvez-Guardiola, Aine Stakelum, Fausto Catena, David Fuks, Des C Winter, Mario Testini, Aleix Martínez-Pérez, SFC Study Group
Apr 30, 2021
BACKGROUND: The effectiveness of surgical treatment for splenic flexure carcinomas (SFCs) in emergency settings remains unexplored. This study aims to compare the perioperative and long-term outcomes of different alternatives...
On the appearance of nitrite anion in [PdX(OAc)L<sub>2</sub>] and [Pd(X)(C∧N)L] syntheses (X = OAc or NO<sub>2</sub>)
S E Bajwa, T E Storr, Lauren E Hatcher, T J Williams, C G Baumann, A C Whitwood, D R Allan, S J Teat, Paul R Raithby, I J S Fairlamb
May 01, 2012
Pd 3(OAc) 5NO 2, an impurity in "Pd(OAc) 2" {formally Pd 3(OAc) 6}, emerges as a serious issue in the synthesis of pure Pd II complexes derived from Pd(OAc) 2, for example in our C-H activation precatalyst, Pd(OAc) 2(pip) 2 (pip...
An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment.
Marcus Jepson, Daisy Elliott, Carmel Conefrey, Julia Wade, Leila Rooshenas, Caroline Wilson, David Beard, Jane M Blazeby, Alison Birtle, Alison Halliday, Rob Stein, Jenny L Donovan, CSAW study group, Chemorad study group, POUT study group, ACST-2 study group, OPTIMA prelim study group
Aug 23, 2018
OBJECTIVES: To explore how the concept of randomization is described by clinicians and understood by patients in randomized controlled trials (RCTs) and how it contributes to patient understanding and recruitment. STUDY DESIGN...
Patient information qualitative research randomization Randomized controlled trials Recruitment Recruitment to RCTs Comprehension Decision Making Computer-Assisted Gambling Humans metaphor Patient Education as Topic Patient Selection qualitative research Random Allocation Randomized Controlled Trials as Topic United Kingdom
|
|< |
< |
1 |